Published in Arthritis Rheum on May 01, 1979
Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. J Clin Invest (1986) 5.72
Antibodies of patients with Lyme disease to components of the Ixodes dammini spirochete. J Clin Invest (1983) 4.08
Laboratory aspects of Lyme borreliosis. Clin Microbiol Rev (1988) 2.18
Lyme borreliosis in the severe combined immunodeficiency (scid) mouse manifests predominantly in the joints, heart, and liver. Am J Pathol (1990) 2.15
Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway. Infect Immun (1988) 1.97
Lyme borreliosis: host responses to Borrelia burgdorferi. Microbiol Rev (1991) 1.87
Specific and nonspecific responses of murine B cells to membrane blebs of Borrelia burgdorferi. Infect Immun (1993) 1.77
Lyme disease. West J Med (1991) 0.99
The antibody response in Lyme disease. Yale J Biol Med (1985) 0.98
Cellular immune findings in Lyme disease. Yale J Biol Med (1985) 0.93
Comparison of polymerase chain reaction with culture and serology for diagnosis of murine experimental Lyme borreliosis. J Clin Microbiol (1993) 0.92
The pathogenesis of arthritis in Lyme disease: humoral immune responses and the role of intra-articular immune complexes. Yale J Biol Med (1985) 0.89
Resolution of Lyme arthritis, acute or prolonged: a new look. Inflammation (2000) 0.78
Lyme disease: a unique human model for an infectious etiology of rheumatic disease. Yale J Biol Med (1985) 0.78
Close to home: a history of Yale and Lyme disease. Yale J Biol Med (2011) 0.78
Lyme disease in northern California. West J Med (1983) 0.78
Parvovirus B19 infection, hepatitis C virus infection, and mixed cryoglobulinaemia. Ann Rheum Dis (1998) 0.75
The spirochetal etiology of Lyme disease. N Engl J Med (1983) 21.59
Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis Rheum (1977) 9.14
Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum. Ann Intern Med (1977) 7.42
Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med (1976) 7.00
Western blotting in the serodiagnosis of Lyme disease. J Infect Dis (1993) 6.45
Two novel classes of small ribonucleoproteins detected by antibodies associated with lupus erythematosus. Science (1981) 6.34
The early clinical manifestations of Lyme disease. Ann Intern Med (1983) 5.73
Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. J Clin Invest (1986) 5.72
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 5.41
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
Cases of Lyme disease in the United States: locations correlated with distribution of Ixodes dammini. Ann Intern Med (1979) 4.73
C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol (1969) 4.38
A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med (2001) 4.35
The dissociation by colchicine of phagocytosis from increased oxygen consumption in human leukocytes. J Clin Invest (1967) 4.22
Mechanism of interaction between Ku protein and DNA. J Biol Chem (1986) 4.22
Lyme carditis: cardiac abnormalities of Lyme disease. Ann Intern Med (1980) 4.12
Antibodies of patients with Lyme disease to components of the Ixodes dammini spirochete. J Clin Invest (1983) 4.08
Comparison of immunoblotting and indirect enzyme-linked immunosorbent assay using different antigen preparations for diagnosing early Lyme disease. J Infect Dis (1988) 4.08
Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med (1994) 4.07
Antibody response in Lyme disease: evaluation of diagnostic tests. J Infect Dis (1984) 4.07
Microtubular crystals in mammalian cells. J Cell Biol (1969) 3.98
Neurologic abnormalities of Lyme disease. Medicine (Baltimore) (1979) 3.98
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science (1998) 3.68
A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med (1998) 3.62
The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis. Neurology (1985) 3.55
Chronic neurologic manifestations of Lyme disease. N Engl J Med (1990) 3.54
Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE. J Clin Microbiol (1999) 3.41
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
Direct demonstration of antigenic substitution of Borrelia burgdorferi ex vivo: exploration of the paradox of the early immune response to outer surface proteins A and C in Lyme disease. J Exp Med (1996) 3.23
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Intern Med (1994) 3.20
A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component. J Immunol (1967) 3.18
The complement system of man. I. N Engl J Med (1972) 3.09
Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun (1993) 3.04
Experimental Lyme arthritis in rats infected with Borrelia burgdorferi. J Infect Dis (1988) 3.02
Antibiotic therapy in Lyme disease. Ann Intern Med (1980) 2.93
Cytochalasin B reversibly inhibits phagocytosis: functional, metabolic, and ultrastructural effects in human blood leukocytes and rabbit alveolar macrophages. Yale J Biol Med (1971) 2.91
A distinct endothelial cell recognition system that controls lymphocyte traffic into inflamed synovium. Science (1986) 2.91
Lyme disease: recommendations for diagnosis and treatment. Ann Intern Med (1991) 2.91
Treatment of the early manifestations of Lyme disease. Ann Intern Med (1983) 2.89
Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. J Biol Chem (1986) 2.79
DNA characterization of the spirochete that causes Lyme disease. J Clin Microbiol (1984) 2.71
Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. Science (1976) 2.70
Binding of Ku protein to DNA. Measurement of affinity for ends and demonstration of binding to nicks. J Biol Chem (1993) 2.66
Activation of the properdin pathway of complement in patients with gram-negative of bacteremia. N Engl J Med (1975) 2.63
Induction of autoreactive B cells allows priming of autoreactive T cells. J Exp Med (1991) 2.60
Detection of Borrelia burgdorferi DNA in museum specimens of Ixodes dammini ticks. Science (1990) 2.58
Complement receptor binding of C3b-coated cells treated with C3b inactivator, beta 1H globulin and trypsin. J Immunol (1979) 2.58
Humoral immune response to outer surface protein C of Borrelia burgdorferi in Lyme disease: role of the immunoglobulin M response in the serodiagnosis of early infection. Infect Immun (1994) 2.57
Erythema chronicum migrans and Lyme arthritis: epidemiologic evidence for a tick vector. Am J Epidemiol (1978) 2.53
The complement system in rheumatoid synovitis. I. An analysis of complement component activities in rheumatoid synovial fluids. Arthritis Rheum (1971) 2.53
Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. A cost-effectiveness analysis. Ann Intern Med (1993) 2.52
Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin. Ann Intern Med (1983) 2.50
The lupus autoantigens and the pathogenesis of systemic lupus erythematosus. Arthritis Rheum (1986) 2.49
Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med (1997) 2.48
Loss with age in NZB-W mice of thymic suppressor cells in the graft-vs-host reaction. J Immunol (1974) 2.45
Microtubule crystals: a new biophysical phenomenon induced by Vinca alkaloids. Nature (1968) 2.41
Diagnosing early Lyme disease. Am J Med (1985) 2.41
Handwashing practices for the prevention of nosocomial infections. Ann Intern Med (1975) 2.36
Intralaboratory reliability of serologic and urine testing for Lyme disease. Am J Med (2001) 2.34
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med (1985) 2.23
Possible nosocomial transmission of group B streptococci in a newborn nursery. J Pediatr (1975) 2.21
Properdin factor D. II. Activation to D by properdin. J Exp Med (1974) 2.19
Vinblastine and griseofulvin reversibly disrupt the living mitotic spindle. Science (1968) 2.19
Treatment of early Lyme disease. Am J Med (1992) 2.18
Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein. Immunology (1970) 2.17
Clinical pathologic correlations of Lyme disease by stage. Ann N Y Acad Sci (1988) 2.16
Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol (1987) 2.12
Balance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet (1993) 2.05
Fatal pancarditis in a patient with coexistent Lyme disease and babesiosis. Demonstration of spirochetes in the myocardium. Ann Intern Med (1985) 2.04
Lyme arthritis. Spirochetes found in synovial microangiopathic lesions. Am J Pathol (1985) 2.03
Congenital heart block in newborns of mothers with connective tissue disease. Circulation (1977) 2.02
Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi. Arthritis Rheum (1999) 2.01
DNA-dependent protein kinase (Ku protein-p350 complex) assembles on double-stranded DNA. Proc Natl Acad Sci U S A (1994) 2.01
Human antibody responses to VlsE antigenic variation protein of Borrelia burgdorferi. J Clin Microbiol (1999) 1.95
Structural polymorphism of the fourth component of human complement. J Clin Invest (1969) 1.91
Breaking T cell tolerance with foreign and self co-immunogens. A study of autoimmune B and T cell epitopes of cytochrome c. J Immunol (1992) 1.89
Circulating Borrelia burgdorferi in patients with acute Lyme disease: results of blood cultures and serum DNA analysis. J Infect Dis (1993) 1.88
Rheumatoid arthritis. Biosynthesis of complement proteins by synovial tissues. N Engl J Med (1974) 1.88
The serum bactericidal reaction. 3. Antibody and complement requirements for killing a rough Escherichia coli. J Immunol (1969) 1.87
High endothelial differentiation in human lymphoid and inflammatory tissues defined by monoclonal antibody HECA-452. Am J Pathol (1988) 1.86
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85